FDA Approves Taiho Oncology’s LONSURF® (trifluridine/tipiracil) for Adult Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

PRINCETON, N.J., February 25, 2019 – Taiho Oncology, Inc. today announced that the United States Food and Drug Administration (FDA) has approved LONSURF® as a treatment for adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy.

“The approval of LONSURF represents a significant milestone for patients living with advanced gastric or GEJ adenocarcinoma who have limited effective treatment options after standard treatment options have failed,” said Timothy Whitten, President and Chief Executive Officer, Taiho Oncology, Inc. “We thank all the patients and physicians who helped make this possible through their participation in LONSURF clinical trials.”

The approval for LONSURF follows an FDA Priority Review designation and is based on data from a global, randomized, Phase III TAGS trial evaluating LONSURF plus best supportive care (BSC) versus placebo plus BSC in patients with previously treated advanced gastric cancer or GEJ adenocarcinoma following progression or intolerance to previous lines of standard therapy. The trial met its primary and secondary endpoints demonstrating prolonged overall survival (OS) with LONSURF versus placebo, and a safety profile consistent with prior experience with this drug. Full results from the TAGS trial were presented at the European Society of Medical Oncology (ESMO) 2018 Congress with a simultaneous publication in The Lancet Oncology.¹

“Effective treatments for patients with heavily pretreated advanced gastric and GEJ cancer are limited,” said Martin Birkhofer, MD, Senior Vice President and Chief Medical Officer, Taiho Oncology, Inc. “By improving survival, LONSURF may provide a significant impact on the lives of these patients.”

This approval expands the current indication for LONSURF in the United States, where it is currently approved for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with standard chemotherapy, based on results obtained in the RECOURSE trial.²³

About TAGS
TAGS (TAS-102 Gastric Study) is a Taiho-sponsored, global, randomized, double-blind Phase III study evaluating trifluridine/tipiracil (TAS-102) plus BSC versus placebo plus BSC in patients with metastatic gastric or GEJ cancer, refractory to standard treatments. The primary endpoint in the TAGS trial was OS, and the main secondary
endpoint measures included progression-free survival (PFS), safety and tolerability, as well as quality of life. The study enrolled 507 adult patients with metastatic gastric or GEJ cancer who had previously received at least two prior regimens for advanced disease and was conducted in 17 countries and 110 sites around the world.


About RECOURSE
The RECOURSE trial was a global, randomized, double-blind, placebo-controlled Phase III comparison trial evaluating the efficacy and safety of orally administered TAS-102 in patients with previously treated mCRC. The trial enrolled 800 patients in North America, Japan, Europe and Australia. Patients were randomized (2:1) to receive TAS-102 (35 mg/m²) or placebo, plus best supportive care, twice daily. The study met its primary and secondary endpoints of OS and PFS versus placebo.

About Gastric Cancer
Gastric cancer is the fifteenth most commonly diagnosed cancer in the United States (U.S.). In 2018, there were an estimated 26,240 new cases and 10,800 deaths in the U.S. Approximately 35 percent of U.S. patients with gastric cancer are diagnosed at the distant or metastasized stage. Metastatic gastric cancer (mGC) is associated with a five-year survival rate of about 5 percent.

Standard chemotherapy regimens for advanced gastric cancer include fluoropyrimidines, platinum derivatives, and taxanes (with ramucirumab), or irinotecan. After failure of first- and second-line therapies, subsequent treatment options are limited.

About LONSURF
LONSURF consists of a thymidine-based nucleoside analog, trifluridine, and the thymidine phosphorylase (TP) inhibitor, tipiracil, which increases trifluridine exposure by inhibiting its metabolism by TP. Trifluridine is incorporated into DNA, resulting in DNA dysfunction and inhibition of cell proliferation.

In Japan, Taiho Pharmaceutical Co., Ltd. has been marketing LONSURF for the treatment of unresectable advanced or recurrent colorectal cancer since 2014. Taiho Oncology, Inc., a U.S. subsidiary of Taiho Pharmaceutical, has been marketing LONSURF in the United States for metastatic CRC refractory to prior therapy, since receiving FDA approval in 2015. Taiho Pharmaceutical and Servier* are in an exclusive license agreement for the co-development and commercialization of LONSURF in Europe and other countries outside of the United States, Canada, Mexico, and Asia.

As of February 2019, LONSURF has been approved as a treatment option for advanced mCRC in 66 countries and regions worldwide.
Important Safety Information

WARNINGS AND PRECAUTIONS

Severe Myelosuppression:

LONSURF caused severe and life-threatening myelosuppression (Grade 3-4) consisting of neutropenia (38%), anemia (18%), thrombocytopenia (5%), and febrile neutropenia (3%). Two patients (0.2%) died due to neutropenic infection. A total of 12% of LONSURF-treated patients received granulocyte-colony stimulating factors. Obtain complete blood counts prior to and on day 15 of each cycle of LONSURF and more frequently as clinically indicated. Withhold LONSURF for febrile neutropenia, absolute neutrophil count less than 500/mm$^3$, or platelets less than 50,000/mm$^3$. Upon recovery, resume LONSURF at a reduced dose as clinically indicated.

Embryo-Fetal Toxicity:

LONSURF can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment and for at least 6 months after the final dose.

USE IN SPECIFIC POPULATIONS

Lactation: It is not known whether LONSURF or its metabolites are present in human milk. There are no data to assess the effects of LONSURF or its metabolites on the breast-fed infant or the effects on milk production. Because of the potential for serious adverse reactions in breast-fed infants, advise women not to breastfeed during treatment with LONSURF and for 1 day following the final dose.

Male Contraception: Because of the potential for genotoxicity, advise males with female partners of reproductive potential to use condoms during treatment with LONSURF and for at least 3 months after the final dose.

Geriatric Use: Patients 65 years of age or over who received LONSURF had a higher incidence of the following compared to patients younger than 65 years: Grade 3 or 4 neutropenia (46% vs 32%), Grade 3 anemia (22% vs 16%), and Grade 3 or 4 thrombocytopenia (7% vs 4%).

Hepatic Impairment: Do not initiate LONSURF in patients with baseline moderate or severe (total bilirubin greater than 1.5 times ULN and any AST) hepatic impairment. Patients with severe hepatic impairment (total bilirubin greater than 3 times ULN and any AST) were not studied. No adjustment to the starting dose of LONSURF is recommended for patients with mild hepatic impairment.
Renal Impairment: No adjustment to the starting dosage of LONSURF is recommended in patients with mild or moderate renal impairment (CLcr of 30 to 89 mL/min). Patients with severe renal impairment (CLcr < 30 mL/min) were not studied.

ADVERSE REACTIONS

Most Common Adverse Drug Reactions in Patients Treated With LONSURF (≥5%): The most common adverse drug reactions in LONSURF-treated patients vs placebo-treated patients with mCRC, respectively, were asthenia/fatigue (52% vs 35%), nausea (48% vs 24%), decreased appetite (39% vs 29%), diarrhea (32% vs 12%), vomiting (28% vs 14%), infections (27% vs 16%), abdominal pain (21% vs 18%), pyrexia (19% vs 14%), stomatitis (8% vs 6%), dysgeusia (7% vs 2%), and alopecia (7% vs 1%). In metastatic gastric cancer or gastroesophageal junction (GEJ), the most common adverse drug reactions, respectively were, nausea (37% vs 32%), decreased appetite (34% vs 31%), vomiting (25% vs 20%), infections (23% vs 16%) and diarrhea (23% vs 14%).

Pulmonary emboli occurred more frequently in LONSURF-treated patients compared to placebo: (2% vs 0%) in mCRC and (3% vs 2%) in metastatic gastric cancer and GEJ.

Interstitial lung disease (0.2%), including fatalities, has been reported in clinical studies and clinical practice settings in Asia.

Laboratory Test Abnormalities in Patients Treated With LONSURF: Laboratory test abnormalities in LONSURF-treated patients vs placebo-treated patients with mCRC, respectively, were anemia (77% vs 33%), neutropenia (67% vs 1%), and thrombocytopenia (42% vs 8%). In metastatic gastric cancer or GEJ, the test abnormalities, respectively, were neutropenia (66% vs 4%), anemia (63% vs 38%), and thrombocytopenia (34% vs 9%).

Please see full Prescribing Information. [https://www.taihooncology.com/us/prescribing-information.pdf](https://www.taihooncology.com/us/prescribing-information.pdf)

Indications and Use

LONSURF is indicated for the treatment of adult patients with metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.

LONSURF is indicated for the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy.

About Taiho Oncology, Inc. (U.S.)
Taiho Oncology, Inc., a subsidiary of Taiho Pharmaceutical Co., Ltd. and Otsuka Holdings Co., Ltd., has established a world class clinical development organization that works urgently to develop innovative cancer treatments and has built a commercial business in the U.S. Taiho has an oral oncology pipeline consisting of both antimetabolic agents and selectively targeted agents. Advanced technology, dedicated researchers, and state of the art facilities are helping us to define the way the world treats cancer. It’s our work; it’s our passion; it’s our legacy.

For more information about Taiho Oncology, please visit: https://www.taihooncology.com.

**About Taiho Pharmaceutical Co., Ltd. (Japan)**
Taiho Pharmaceutical, a subsidiary of Otsuka Holdings Co., Ltd., is an R&D-driven specialty pharma focusing on the three fields of oncology, allergy and immunology, and urology. Its corporate philosophy takes the form of a pledge: “We strive to improve human health and contribute to a society enriched by smiles.” In the field of oncology in particular, Taiho Pharmaceutical is known as a leading company in Japan for developing innovative medicines for the treatment of cancer, a reputation that is rapidly expanding through their extensive global R&D efforts. In areas other than oncology, as well, the company creates and markets quality products that effectively treat medical conditions and can help improve people’s quality of life. Always putting customers first, Taiho Pharmaceutical also aims to offer consumer healthcare products that support people’s efforts to lead fulfilling and rewarding lives.

For more information about Taiho Pharmaceutical, please visit: https://www.taiho.co.jp/en/.

**About Otsuka Holdings Co., Ltd. (Japan)**
The Otsuka group of companies is a total-healthcare enterprise that aims to contribute to the health of people around the world under the corporate philosophy, “Otsuka-people creating new products for better health worldwide.”

Healthcare is broadly and holistically addressed through the two main pillars – the pharmaceutical business for the diagnosis and treatment of diseases and the nutraceutical*¹ business to support the maintenance and promotion of everyday health. Our 47,000*² employees across 189 companies in 30 countries and regions take on challenges across various fields and themes to help fulfill the universal wish of people to be healthy. Our pursuit of these challenges is motivated by the Otsuka’s corporate culture, articulated as “Ryukan-godo” (by sweat we recognize the way), “Jissho” (actualization) and “Sozosei” (creativity), and fostered by successive generations of Otsuka leaders. By striving to provide unique products and services, we seek to achieve sustainable growth and be an indispensable contributor to the world.

For more information, please visit the company’s website at https://www.otsuka.com/en/.
*1. Nutraceuticals: nutrition + pharmaceuticals *2. As of end of December 2018

###

**U.S. Media Contact:**
Laney Landsman
GCI Health on behalf of Taiho Oncology
Taihooncology@gcihealth.com
646-946-6690

LON-PM-US-1213 02/2019

---


HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use LONSURF safely and effectively. See full prescribing information for LONSURF.

LONSURF (trifluridine and tipiracil) tablets, for oral use
Initial U.S. Approval: 2015

RECENT MAJOR CHANGES
[Indications and Usage (1.2) 2/2019
Recommended Dosage (2.1) 2/2019
Warnings and Precaution (5.1) 2.2019

INDICATIONS AND USAGE
LONSURF is a combination of trifluridine, a nucleoside metabolic inhibitor, and tipiracil, a thymidine phosphorylase inhibitor, indicated for the treatment of adult patients with:
• metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy. (1.1)
• metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy. (1.2)

DOSAGE AND ADMINISTRATION
• Recommended dosage: 35 mg/m²/dose orally twice daily with food on Days 1 through 5 and Days 8 through 12 of each 28-day cycle. (2.1)

DOSAGE FORMS AND STRENGTHS
Tablets:
• 15 mg trifluridine/6.14 mg tipiracil (3)
• 20 mg trifluridine/8.19 mg tipiracil (3)

CONTRAINDICATIONS
None. (4)

WARNINGS AND PRECAUTIONS
• Severe Myelosuppression: Obtain complete blood counts prior to and on Day 15 of each cycle. Withhold and resume at next lower LONSURF dosage as recommended. (2.1, 5.1)
• Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception. (5.2, 8.1, 8.3)

ADVERSE REACTIONS
The most common adverse reactions or laboratory abnormalities (≥10%) are anemia, neutropenia, fatigue/asthenia, nausea, thrombocytopenia, decreased appetite, diarrhea, vomiting, and pyrexia (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Taiho Oncology, Inc. at 1-844-878-2446 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

USE IN SPECIFIC POPULATIONS
• Lactation: Advise not to breastfeed. (8.2)
• Geriatric Use: Grade 3 or 4 neutropenia and thrombocytopenia and Grade 3 anemia occurred more commonly in patients 65 years or older. (8.5)
• Hepatic Impairment: Do not initiate LONSURF in patients with baseline moderate or severe hepatic impairment. (8.7)

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling Revised: 2/2019

FULL PRESCRIBING INFORMATION: CONTENTS*
1 INDICATIONS AND USAGE
1.1 Metastatic Colorectal Cancer
1.2 Metastatic Gastric Cancer
2 DOSAGE AND ADMINISTRATION
2.1 Recommended Dosage
2.2 Dosage Modifications for Adverse Reactions
3 DOSAGE FORMS AND STRENGTHS
4 CONTRAINDICATIONS
5 WARNINGS AND PRECAUTIONS
5.1 Severe Myelosuppression
5.2 Embryo-Fetal Toxicity
6 ADVERSE REACTIONS
6.1 Clinical Trials Experience
8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
8.2 Lactation
8.3 Females and Males of Reproductive Potential
8.4 Pediatric Use
8.5 Geriatric Use
8.6 Renal Impairment
8.7 Hepatic Impairment
11 DESCRIPTION
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
12.2 Pharmacodynamics
12.3 Pharmacokinetics
13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
14 CLINICAL STUDIES
14.1 Metastatic Colorectal Cancer
14.2 Metastatic Gastric Cancer
15 REFERENCES
16 HOW SUPPLIED/STORAGE AND HANDLING
17 PATIENT COUNSELING INFORMATION
*Sections or subsections omitted from the full prescribing information are not listed.
FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

1.1 Metastatic Colorectal Cancer
LONSURF is indicated for the treatment of adult patients with metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.

1.2 Metastatic Gastric Cancer
LONSURF is indicated for the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy.

2 DOSAGE AND ADMINISTRATION

2.1 Recommended Dosage
The recommended dosage of LONSURF is 35 mg/m² up to a maximum of 80 mg per dose (based on the trifluridine component) orally twice daily with food on Days 1 through 5 and Days 8 through 12 of each 28-day cycle until disease progression or unacceptable toxicity. Round dose to the nearest 5 mg increment.

Instruct patients to swallow LONSURF tablets whole.

Instruct patients not to retake doses of LONSURF that are vomited or missed and to continue with the next scheduled dose.

LONSURF is a cytotoxic drug. Follow applicable special handling and disposal procedures. Table 1 shows the calculated initial daily dose based on body surface area (BSA).
Table 1  Dose According to Body Surface Area (BSA)

<table>
<thead>
<tr>
<th>BSA (m²)</th>
<th>Total daily dose (mg)</th>
<th>Dose (mg) administered twice daily</th>
<th>Tablets per dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 1.07</td>
<td>70</td>
<td>35</td>
<td>15mg 20mg</td>
</tr>
<tr>
<td>1.07 - 1.22</td>
<td>80</td>
<td>40</td>
<td>0 2</td>
</tr>
<tr>
<td>1.23 - 1.37</td>
<td>90</td>
<td>45</td>
<td>3 0</td>
</tr>
<tr>
<td>1.38 - 1.52</td>
<td>100</td>
<td>50</td>
<td>2 1</td>
</tr>
<tr>
<td>1.53 - 1.68</td>
<td>110</td>
<td>55</td>
<td>1 2</td>
</tr>
<tr>
<td>1.69 - 1.83</td>
<td>120</td>
<td>60</td>
<td>0 3</td>
</tr>
<tr>
<td>1.84 - 1.98</td>
<td>130</td>
<td>65</td>
<td>3 1</td>
</tr>
<tr>
<td>1.99 - 2.14</td>
<td>140</td>
<td>70</td>
<td>2 2</td>
</tr>
<tr>
<td>2.15 - 2.29</td>
<td>150</td>
<td>75</td>
<td>1 3</td>
</tr>
<tr>
<td>≥2.30</td>
<td>160</td>
<td>80</td>
<td>0 4</td>
</tr>
</tbody>
</table>

2.2 Dosage Modifications for Adverse Reactions

Obtain complete blood cell counts prior to and on Day 15 of each cycle [see Warnings and Precautions (5.1)].

Do not initiate the cycle of LONSURF until:

- Absolute neutrophil count (ANC) greater than or equal to 1,500/mm³ or febrile neutropenia is resolved
- Platelets greater than or equal to 75,000/mm³
- Grade 3 or 4 non-hematological adverse reactions are resolved to Grade 0 or 1

Within a treatment cycle, withhold LONSURF for any of the following:

- Absolute neutrophil count (ANC) less than 500/mm³ or febrile neutropenia
- Platelets less than 50,000/mm³
- Grade 3 or 4 non-hematologic adverse reaction

After recovery, resume LONSURF after reducing the dose by 5 mg/m²/dose from the previous dose, if the following occur:

- Febrile neutropenia
- Uncomplicated Grade 4 neutropenia (which has recovered to greater than or equal to 1,500/mm³) or thrombocytopenia (which has recovered to greater than or equal to 75,000/mm³) that results in more than 1 week delay in start of next cycle
- Non-hematologic Grade 3 or Grade 4 adverse reaction except for Grade 3 nausea and/or vomiting controlled by antiemetic therapy or Grade 3 diarrhea responsive to antidiarrheal medication

A maximum of 3 dose reductions are permitted. Permanently discontinue LONSURF in patients who are unable to tolerate a dose of 20 mg/m² orally twice daily. Do not escalate LONSURF dosage after it has been reduced.
3 DOSAGE FORMS AND STRENGTHS

Tablets:

- 15 mg trifluridine/6.14 mg tipiracil: white, biconvex, round, film-coated, imprinted with ‘15’ on one side, and ‘102’ and ‘15 mg’ on the other side, in gray ink.

- 20 mg trifluridine/8.19 mg tipiracil: pale red, biconvex, round, film-coated, imprinted with ‘20’ on one side, and ‘102’ and ‘20 mg’ on the other side, in gray ink.

4 CONTRAINDICATIONS

None.

5 WARNINGS AND PRECAUTIONS

5.1 Severe Myelosuppression

In the 868 patients who received LONSURF in RECOURSE and TAGS, LONSURF caused severe and life-threatening myelosuppression (Grade 3-4) consisting of anemia (18%), neutropenia (38%), thrombocytopenia (5%) and febrile neutropenia (3%). Two patients (0.2%) died due to neutropenic infection/sepsis and four other patients (0.5%) died due to septic shock. A total of 12% of LONSURF-treated patients received granulocyte-colony stimulating factors.

Obtain complete blood counts prior to and on Day 15 of each cycle of LONSURF and more frequently as clinically indicated. Withhold LONSURF for severe myelosuppression and resume at the next lower dosage [see Dosage and Administration (2.2)].

5.2 Embryo-Fetal Toxicity

Based on animal studies and its mechanism of action, LONSURF can cause fetal harm when administered to a pregnant woman. Trifluridine/tipiracil caused embryo-fetal lethality and embryo-fetal toxicity in pregnant rats when orally administered during gestation at dosage levels resulting in exposures lower than those achieved at the recommended dosage of 35 mg/m² twice daily. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use an effective method of contraception during treatment with LONSURF and for at least 6 months after the final dose [see Use in Specific Populations (8.1, 8.3)].

6 ADVERSE REACTIONS

The following clinically significant adverse reactions are described elsewhere in the labeling:

- Severe Myelosuppression [see Warnings and Precautions (5.1)]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The data in the WARNINGS AND PRECAUTIONS section and below reflect exposure to LONSURF at the recommended dose in 533 patients with metastatic colorectal cancer in RECOURSE and 335 patients with metastatic gastric cancer in TAGS. Among the 868 patients who received LONSURF, 11% were exposed for 6 months or longer and 1% were exposed for 12 months or longer. The most common adverse reactions or laboratory abnormalities (≥10%) are anemia, neutropenia, fatigue/asthenia, nausea, thrombocytopenia, decreased appetite, diarrhea, vomiting, and pyrexia.

Metastatic Colorectal Cancer

The safety of LONSURF was evaluated in RECOURSE, a randomized (2:1), double-blind, placebo-controlled trial in patients with previously treated metastatic colorectal cancer [see Clinical Studies (14.1)]. Patients received LONSURF 35 mg/m²/dose (n=533) or placebo (n=265) twice daily on Days 1 through 5 and Days 8 through 12 of each 28-day cycle. In RECOURSE, 12% of patients received LONSURF for more than 6 months and 1% of patients received LONSURF for more than 1 year.

The study population characteristics were: median age 63 years; 61% male; 57% White, 35% Asian, and 1% Black.

The most common adverse reactions or laboratory abnormalities (≥10% in incidence) in patients treated with LONSURF at a rate that exceeds the rate in patients receiving placebo were anemia, neutropenia, asthenia/fatigue, nausea, thrombocytopenia, decreased appetite, diarrhea, vomiting, abdominal pain, and pyrexia.

In RECOURSE, 3.6% of patients discontinued LONSURF for an adverse reaction and 14% of patients required a dose reduction. The most common adverse reactions or laboratory abnormalities leading to dose reduction were neutropenia, anemia, febrile neutropenia, fatigue, and diarrhea.

Tables 2 and 3 list the adverse reactions and laboratory abnormalities (graded using CTCAE v4.03), respectively, observed in RECOURSE.
Table 2  Adverse Reactions (≥5%) in Patients Receiving LONSURF and at a Higher Incidence (>2%) than in Patients Receiving Placebo in RECOURSE

<table>
<thead>
<tr>
<th>Adverse Reactions</th>
<th></th>
<th>LONSURF</th>
<th></th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>(N=533)</td>
<td></td>
<td>(N=265)</td>
</tr>
<tr>
<td></td>
<td>All Grades (%)</td>
<td>Grades 3-4* (%)</td>
<td>All Grades (%)</td>
<td>Grades 3-4* (%)</td>
</tr>
<tr>
<td>General</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asthenia/fatigue</td>
<td>52</td>
<td>7</td>
<td>35</td>
<td>9</td>
</tr>
<tr>
<td>Pyrexia</td>
<td>19</td>
<td>1</td>
<td>14</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nausea</td>
<td>48</td>
<td>2</td>
<td>24</td>
<td>1</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>32</td>
<td>3</td>
<td>12</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Vomiting</td>
<td>28</td>
<td>2</td>
<td>14</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>21</td>
<td>2</td>
<td>18</td>
<td>4</td>
</tr>
<tr>
<td>Stomatitis</td>
<td>8</td>
<td>&lt;1</td>
<td>6</td>
<td>0</td>
</tr>
<tr>
<td>Metabolism and nutrition</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Decreased appetite</td>
<td>39</td>
<td>4</td>
<td>29</td>
<td>5</td>
</tr>
<tr>
<td>Infections†</td>
<td>27</td>
<td>6</td>
<td>16</td>
<td>5</td>
</tr>
<tr>
<td>Nervous system</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dysgeusia</td>
<td>7</td>
<td>0</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Skin and subcutaneous tissue</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alopecia</td>
<td>7</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
</tbody>
</table>

*No Grade 4 definition for nausea, abdominal pain, or fatigue in National Cancer Institute Common Terminology
†Incidence reflects 64 preferred terms in the Infections and Infestations system organ class.
### Table 3  Laboratory Abnormalities in RECOUERSE

<table>
<thead>
<tr>
<th>Laboratory Parameter</th>
<th>LONSURF</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>All Grades (%)</td>
<td>Grades 3-4 (%)</td>
</tr>
<tr>
<td>Hematologic</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anemia†</td>
<td>77</td>
<td>18</td>
</tr>
<tr>
<td>Neutropenia</td>
<td>67</td>
<td>38</td>
</tr>
<tr>
<td>Thrombocytopenia</td>
<td>42</td>
<td>5</td>
</tr>
</tbody>
</table>

* Worst Grade at least one grade higher than baseline, with percentages based on number of patients with post-baseline samples, which may be <533 (LONSURF) or 265 (placebo)
† One Grade 4 anemia adverse reaction based on clinical criteria was reported

In RECOUERSE, pulmonary emboli occurred more frequently in LONSURF-treated patients (2%) compared to no patients on placebo.

### Metastatic Gastric Cancer

The safety of LONSURF was evaluated in TAGS, an international, randomized (2:1), double-blind, placebo-controlled trial in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma who were previously treated with at least 2 prior chemotherapy regimens for advanced disease [see Clinical Studies (14.2)]. Previous treatments must have included a fluoropyrimidine, a platinum, and either a taxane or irinotecan. Patients with HER2/neu-positive tumors must have received prior HER2/neu-targeted therapy, if available. Adjuvant chemotherapy could be counted as one prior regimen in patients who had recurrence during or within 6 months of completion of the adjuvant chemotherapy. Patients received LONSURF 35 mg/m²/dose (n=335) or placebo (n=168) twice daily on Days 1 through 5 and Days 8 through 12 of each 28-day cycle with best supportive care. In TAGS, 10% of patients received LONSURF for more than 6 months and 0.9% of patients received LONSURF for more than 1 year.

The study population characteristics were: median age 63 years (24 to 89 years); 73% male; 70% White, 16% Asian, and 1% Black.

The most common adverse reactions or laboratory abnormalities (≥10% in incidence) in patients treated with LONSURF at a rate that exceeds the rate in patients receiving placebo were neutropenia, anemia, nausea, decreased appetite, thrombocytopenia, vomiting, and diarrhea.

In TAGS, 13% of patients discontinued LONSURF for an adverse reaction and 11% of patients required a dose reduction. The most common adverse reactions or laboratory abnormalities leading to dose reduction were neutropenia, anemia, febrile neutropenia, and diarrhea.

Tables 4 and 5 list the adverse reactions and laboratory abnormalities (graded using CTCAE v4.03), respectively, observed in TAGS.
### Table 4  Adverse Reactions (≥5%) in Patients Receiving LONSURF and at a Higher Incidence (>2%) than in Patients Receiving Placebo in TAGS

<table>
<thead>
<tr>
<th>Adverse Reactions</th>
<th>LONSURF (N=335)</th>
<th>Placebo (N=168)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>All Grades (%)</td>
<td>Grades 3-4* (%)</td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nausea</td>
<td>37</td>
<td>3</td>
</tr>
<tr>
<td>Vomiting</td>
<td>25</td>
<td>4</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>23</td>
<td>3</td>
</tr>
<tr>
<td>Metabolism and nutrition</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Decreased appetite</td>
<td>34</td>
<td>9</td>
</tr>
<tr>
<td>Infections†</td>
<td>23</td>
<td>5</td>
</tr>
</tbody>
</table>

*No Grade 4 definition for nausea or fatigue in NCI CTCAE, version 4.03.
†Incidence reflects 46 preferred terms in the Infections and Infestations system organ class.

### Table 5  Laboratory Abnormalities in TAGS

<table>
<thead>
<tr>
<th>Laboratory Parameter*</th>
<th>LONSURF</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>All Grades (%)</td>
<td>Grades 3-4 (%)</td>
</tr>
<tr>
<td>Hematologic</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neutropenia</td>
<td>66</td>
<td>38</td>
</tr>
<tr>
<td>Anemia†</td>
<td>63</td>
<td>19</td>
</tr>
<tr>
<td>Thrombocytopenia</td>
<td>34</td>
<td>6</td>
</tr>
</tbody>
</table>

*Worst Grade at least one Grade higher than baseline, with percent based on number of patients with post-baseline samples which may be <335 (LONSURF) or 168 (placebo)
†Anemia: No Grade 4 definition in CTCAE, v4.03

In TAGS, pulmonary emboli occurred more frequently in LONSURF-treated patients (3.1%) compared to 1.8% for patients on placebo.
Additional Clinical Experience
Interstitial lung disease was reported in 15 (0.2%) patients, 3 of which were fatal, among approximately 7,000 patients exposed to LONSURF in clinical studies and clinical practice settings in Asia.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy
Risk Summary
Based on animal data and its mechanism of action [see Clinical Pharmacology (12.2)], LONSURF can cause fetal harm. LONSURF caused embryo-fetal lethality and embryo-fetal toxicity in pregnant rats when given during gestation at doses resulting in exposures lower than or similar to human exposures at the recommended clinical dose (see Data). There are no available data on LONSURF use in pregnant women. Advise pregnant women of the potential risk to a fetus.

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

Data
Animal Data
Trifluridine/tipiracil was administered orally once daily to female rats during organogenesis at dose levels of 15, 50, and 150 mg/kg [trifluridine (FTD) equivalent]. Decreased fetal weight was observed at FTD doses ≥50 mg/kg (approximately 0.33 times the FTD exposure at the clinical dose of 35 mg/m² twice daily). At the FTD dose of 150 mg/kg (approximately 0.92 times the FTD exposure at the clinical dose of 35 mg/m² twice daily) embryolethality and structural anomalies (kinked tail, cleft palate, ectrodactyly, anasarca, alterations in great vessels, and skeletal anomalies) were observed.

8.2 Lactation
Risk Summary
There are no data on the presence of trifluridine, tipiracil or its metabolites in human milk or its effects on the breastfed child or on milk production. In nursing rats, trifluridine and tipiracil or their metabolites were present in breast milk (see Data). Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment with LONSURF and for 1 day following the final dose.

Data
Radioactivity was excreted in the milk of nursing rats dosed with trifluridine/tipiracil containing 14C-FTD or 14C-tipiracil (TPI). Levels of FTD-derived radioactivity were as high as approximately 50% of the exposure in maternal plasma an hour after dosing with trifluridine/tipiracil and were approximately the same as those in maternal plasma for up to 12 hours following dosing. Exposure to TPI-derived radioactivity was higher in milk than in
maternal plasma beginning 2 hours after dosing and continuing for at least 12 hours following administration of trifluridine/tipiracil.

8.3 Females and Males of Reproductive Potential

Pregnancy Testing
Verify pregnancy status in females of reproductive potential prior to initiating LONSURF [see Use in Specific Populations (8.1)].

Contraception
LONSURF can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1)].

Females
Advise females of reproductive potential to use effective contraception during treatment with LONSURF and for at least 6 months after the final dose.

Males
Because of the potential for genotoxicity, advise males with female partners of reproductive potential to use condoms during treatment with LONSURF and for at least 3 months after the final dose [see Nonclinical Toxicology (13.1)].

8.4 Pediatric Use
Safety and effectiveness of LONSURF in pediatric patients have not been established.

Juvenile Animal Toxicity Data
Dental toxicity including whitening, breakage, and malocclusion (degeneration and disarrangement in the ameloblasts, papillary layer cells and odontoblasts) were observed in rats treated with trifluridine/tipiracil at doses $\geq 50$ mg/kg (approximately 0.33 times the exposure at the clinical dose of 35 mg/m$^2$ twice daily).

8.5 Geriatric Use
In RECOURSE and TAGS, 868 patients received LONSURF; 45% were 65 years of age or over, while 10% were 75 and over. No overall differences in effectiveness were observed in patients 65 or older versus younger patients. Patients 65 years of age or older who received LONSURF had a higher incidence of the following hematologic laboratory abnormalities compared to patients younger than 65 years: Grade 3 or 4 neutropenia (46% vs. 32%), Grade 3 anemia (22% vs. 16%), and Grade 3 or 4 thrombocytopenia (7% vs. 4%).

8.6 Renal Impairment
No adjustment to the starting dosage of LONSURF is recommended in patients with mild or moderate renal impairment (CLcr of 30 to 89 mL/min). Patients with severe renal impairment (CLcr $< 30$ mL/min) were not studied [see Clinical Pharmacology (12.3)].
8.7 Hepatic Impairment

No adjustment to the starting dosage of LONSURF is recommended for patients with mild hepatic impairment. Do not initiate LONSURF in patients with baseline moderate or severe (total bilirubin >1.5 times ULN and any AST) hepatic impairment [see Clinical Pharmacology (12.3)].

11 DESCRIPTION

LONSURF contains trifluridine and tipiracil hydrochloride at a molar ratio of 1:0.5.

Trifluridine

Trifluridine, a nucleoside metabolic inhibitor, is described chemically as 2’-deoxy-5-(trifluoromethyl) uridine and has the following structural formula:

![Trifluridine structural formula](image)

Trifluridine has a molecular formula C₁₀H₁₁F₃N₂O₅ and a molecular weight of 296.20. Trifluridine is a white crystalline powder, soluble in water, ethanol, 0.01 mol/L hydrochloric acid, 0.01 mol/L sodium hydroxide solution; freely soluble in methanol, acetone; sparingly soluble in 2-propanol, acetonitrile; slightly soluble in diethyl ether; and very slightly soluble in isopropyl ether.

Tipiracil hydrochloride

Tipiracil hydrochloride, a thymidine phosphorylase inhibitor, is described chemically as 5-chloro-6-[(2-iminopyrroladin-1-yl)methyl]pyrimidine-2,4-(1H,3H)-dione monohydrochloride or 2,4(1H,3H)-Pyrimidinedione, 5-chloro-6-[(2-imino-1-pyrrolidinyl)methyl]-, hydrochloride (1:1) and has the following structural formula:

![Tipiracil hydrochloride structural formula](image)

Tipiracil hydrochloride has a molecular formula C₉H₁₁ClN₄O₂•HCl and a molecular weight of 279.12. Tipiracil hydrochloride is a white crystalline powder, soluble in water, 0.01 mol/L hydrochloric acid, and 0.01 mol/L sodium hydroxide; slightly soluble in methanol; very slightly soluble in ethanol; and practically insoluble in acetonitrile, 2-propanol, acetone, diisopropyl ether, and diethyl ether.
LONSURF (trifluridine and tipracil) tablets for oral use contain 15 mg of trifluridine and 6.14 mg of tipracil equivalent to 7.065 mg of tipiracil hydrochloride or 20 mg of trifluridine and 8.19 mg of tipracil equivalent to 9.420 mg of tipiracil hydrochloride.

LONSURF tablets contain the following inactive ingredients: lactose monohydrate, pregelatinized starch, stearic acid, hypromellose, polyethylene glycol, titanium dioxide, ferric oxide, and magnesium stearate. The tablets are imprinted with ink containing shellac, ferric oxide red, ferric oxide yellow, titanium dioxide, FD&C Blue No. 2 Aluminum Lake, carnauba wax, and talc.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

LONSURF consists of a thymidine-based nucleoside analog, trifluridine, and the thymidine phosphorylase inhibitor, tipiracil, at a molar ratio 1:0.5 (weight ratio, 1:0.471). Inclusion of tipiracil increases trifluridine exposure by inhibiting its metabolism by thymidine phosphorylase. Following uptake into cancer cells, trifluridine is incorporated into DNA, interferes with DNA synthesis and inhibits cell proliferation. Trifluridine/tipiracil demonstrated anti-tumor activity against KRAS wild-type and mutant human colorectal cancer xenografts in mice.

12.2 Pharmacodynamics

Cardiac Electrophysiology

LONSURF administered to 42 patients with advanced solid tumors at the recommended dosage had no large effect (i.e. >20 ms) in the mean QTc interval when compared to placebo and no exposure-QT relationship was identified. Two of 42 patients (4.8%) had QTc >500 msec and 2.4% had a QTc increase from baseline >60 msec.

12.3 Pharmacokinetics

After twice daily dosing of LONSURF, systemic exposure (AUC) of trifluridine increased more than dose-proportionally over the dose range of 15 mg/m² (0.43 times the recommended dose) to 35 mg/m².

The accumulation of trifluridine was 3-fold for AUC_{0-12hr} and 2-fold for C_{max} at steady state while no accumulation was observed for tipiracil.

Administration of a single dose of LONSURF 35 mg/m² increased the mean AUC_{0-last} of trifluridine by 37-fold and C_{max} by 22-fold with reduced variability compared to administration of a single dose of trifluridine 35 mg/m² alone.
Absorption
Following a single oral administration of LONSURF at 35 mg/m² in patients with cancer, the mean time to peak plasma concentration (T_{max}) of trifluridine was around 2 hours.

Food Effect
A standardized high-fat, high-calorie meal decreased trifluridine C_{max}, tipiracil C_{max} and AUC by approximately 40%, but did not change trifluridine AUC compared to those in a fasting state in patients with cancer following administration of a single dose of LONSURF 35 mg/m².

Distribution
Trifluridine mainly binds to human serum albumin. The in vitro protein binding of trifluridine in human plasma is >96%, independent of drug concentration and presence of tipiracil. Plasma protein binding of tipiracil is below 8%.

Elimination
After administration of LONSURF 35 mg/m², the mean elimination half-life (t_{1/2}) of trifluridine was 1.4 hours and of tipiracil was 2.1 hours after a single dose. The mean elimination half-life at steady state of trifluridine was 2.1 hours and of tipiracil was 2.4 hours.

Metabolism
Trifluridine and tipiracil are not metabolized by cytochrome P450 (CYP) enzymes. Trifluridine is mainly eliminated by metabolism via thymidine phosphorylase to form an inactive metabolite, 5-(trifluoromethyl) uracil (FTY). No other major metabolites were detected in plasma or urine.

Excretion
After single oral administration of LONSURF (60 mg) with [14C]-trifluridine, the total cumulative excretion of radioactivity was 60% of the administered dose. The majority of recovered radioactivity was eliminated into urine (55% of the dose) as FTY and trifluridine glucuronide isomers within 24 hours and the excretion into feces and expired air was <3% for both. The unchanged trifluridine was <3% of administered dose recovered in the urine and feces.

After single oral administration of LONSURF (60 mg) with [14C]-tipiracil hydrochloride, recovered radioactivity was 77% of the dose, which consisted of 27% urinary excretion and 50% fecal excretion. Tipiracil was the major component and 6-HMU was the major metabolite in urine, and feces.

Specific Populations
Based on the population pharmacokinetic analysis, there is no clinically relevant effect of age, sex, or race (White or Asian) on the pharmacokinetics of trifluridine or tipiracil.

Patients with Renal Impairment
In RECOURSE, using the Cockcroft-Gault formula for creatinine clearance, the estimated mean AUC of trifluridine at steady state was 31% higher in patients with mild renal impairment (CLcr = 60 to 89 mL/min) and 43% higher in patients with moderate renal impairment (CLcr = 30 to 59 mL/min) than that in patient with normal renal function (CLcr ≥ 90 mL/min). The estimated mean AUC of tipiracil was 34% higher in patients with mild renal impairment and 65% higher in patients with moderate renal impairment than that in patients with normal renal function. The
pharmacokinetics of trifluridine and tipiracil have not been studied in patients with severe renal impairment (CLcr < 30 mL/min) or end-stage renal disease [see Use in Specific Populations (8.7)].

Patients with Hepatic Impairment

No clinically important differences in the mean exposures of trifluridine and tipiracil were observed between patients with mild hepatic impairment (total bilirubin ≤ ULN and AST > ULN or total bilirubin <1 to 1.5 times ULN and any AST) to moderate hepatic impairment (total bilirubin >1.5 to 3 times ULN and any AST) and patients with normal hepatic function (total bilirubin and AST ≤ ULN); however, 5 of 6 patients with moderate hepatic impairment experienced Grade 3 or 4 increased bilirubin levels. The pharmacokinetics of trifluridine and tipiracil have not been studied in patients with severe hepatic impairment [see Dosage Modifications (2.2), Use in Specific Populations (8.6)].

Drug Interaction Studies

In vitro studies indicated that trifluridine, tipiracil, and FTY did not inhibit the CYP enzymes and had no inductive effect on CYP1A2, CYP2B6, or CYP3A4/5.

In vitro studies indicated that trifluridine was not an inhibitor of or substrate for human uptake and efflux transporters.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

No long-term studies evaluating the carcinogenic potential of trifluridine/tipiracil in animals have been performed. Trifluridine/tipiracil was genotoxic in a reverse mutation test in bacteria, a chromosomal aberration test in mammalian-cultured cells, and a micronucleus test in mice. Animal studies did not indicate an effect of trifluridine/tipiracil on male fertility in rats. Dose-related increases in the corpus luteum count and implanted embryo count were observed, but female fertility was not affected.

14 CLINICAL STUDIES

14.1 Metastatic Colorectal Cancer

The efficacy of LONSURF was evaluated in RECOURSE (NCT01607957), an international, randomized, double-blind, placebo-controlled study conducted in patients with previously treated metastatic colorectal cancer (mCRC). Key eligibility criteria included prior treatment with at least 2 lines of standard chemotherapy for metastatic CRC, ECOG performance status (PS) 0-1, absence of brain metastasis, and absence of ascites requiring drainage in the past four weeks. Patients were randomized 2:1 to receive LONSURF 35 mg/m² or matching placebo orally twice daily after meals on Days 1-5 and 8-12 of each 28-day cycle until disease progression or unacceptable toxicity. Randomization was stratified by KRAS status (wild-type vs. mutant), time since diagnosis of first metastasis (<18 months vs. ≥ 18 months), and region (Japan vs. US,
Europe and Australia). The major efficacy outcome measure was overall survival (OS) and an additional efficacy outcome measure was progression-free survival (PFS).

A total of 800 patients were randomized to LONSURF (N=534) with best supportive care (BSC) or matching placebo (N=266) plus BSC. The median age was 63 years, 61% were male, 58% and 35% were White and Asian respectively, and all patients had baseline ECOG PS of 0 or 1. The primary site of disease was colon (62%) or rectum (38%). KRAS status was wild-type (49%) or mutant (51%) at study entry. All patients received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. All but one patient received bevacizumab and all but two patients with KRAS wild-type tumors received panitumumab or cetuximab.

Efficacy results are summarized in Table 7 and Figure 1.

Table 7  Efficacy Results from RECURSE

<table>
<thead>
<tr>
<th></th>
<th>LONSURF (N=534)</th>
<th>Placebo (N=266)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Overall Survival</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of deaths, N (%)</td>
<td>364 (68)</td>
<td>210 (79)</td>
</tr>
<tr>
<td>Median OS (months) a (95% CI) b</td>
<td>7.1 (6.5, 7.8)</td>
<td>5.3 (4.6, 6.0)</td>
</tr>
<tr>
<td>Hazard ratio (95% CI)</td>
<td></td>
<td>0.68 (0.58, 0.81)</td>
</tr>
<tr>
<td>p-value c</td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>Progression-Free Survival</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of events, N (%)</td>
<td>472 (88)</td>
<td>251 (94)</td>
</tr>
<tr>
<td>Hazard ratio (95% CI)</td>
<td></td>
<td>0.47 (0.40, 0.55)</td>
</tr>
<tr>
<td>p-value c</td>
<td></td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

a Kaplan-Meier estimates
b Methodology of Brookmeyer and Crowley
c Stratified log-rank test (strata: KRAS status, time since diagnosis of first metastasis, region), 2-sided
The efficacy of LONSURF was evaluated in TAGS (NCT02500043), an international, randomized, double-blind, placebo-controlled study in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma previously treated with at least 2 prior regimens for advanced disease. Previous treatments must have included a fluoropyrimidine, a platinum, and either a taxane or irinotecan. Patients with HER2/neu-positive tumors must have received prior HER2/neu-targeted therapy, if available. Adjuvant chemotherapy could be counted as one prior regimen in patients who had recurrence during or within 6 months of completion of the adjuvant chemotherapy. Other key eligibility criteria included ECOG performance status (PS) 0 or 1. Patients were randomized 2:1 to receive LONSURF 35 mg/m² orally twice daily on Days 1-5 and 8-12 of each 28-day cycle with best supportive care (BSC) or matching placebo with BSC until disease progression or unacceptable toxicity. Randomization was stratified by ECOG PS at baseline (0 vs. 1), prior ramucirumab (yes vs. no), and geographic region (Japan vs. rest of world). The major efficacy outcome measure was OS and an additional outcome measure was PFS.

A total of 507 patients were randomized to LONSURF (N=337) or placebo (N=170). The median age was 63 years, 73% were male, 70% and 16% were White and Asian respectively, and 38% had a baseline ECOG PS of 0. Seventy-one percent of patients had gastric tumors, 29% had GEJ tumors, and two patients had gastric/GEJ tumors. All patients received platinum-based chemotherapy, 99% received fluoropyrimidine-based therapy, 91% received a taxane, 55% received irinotecan, and 33% received ramucirumab. The HER2 status was negative in 62%, positive in 19%, and unknown in 20% of patients. Among the 94 patients with HER2 positive tumors, 89% received prior anti-HER2 therapy.

Efficacy results are summarized in Table 8 and Figure 2.
Table 8  Efficacy Results from TAGS

<table>
<thead>
<tr>
<th></th>
<th>LONSURF (N=337)</th>
<th>Placebo (N=170)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Overall Survival</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of deaths, N (%)</td>
<td>244 (72)</td>
<td>140 (82)</td>
</tr>
<tr>
<td>Median OS (months)(^a) (95% CI)(^b)</td>
<td>5.7 (4.8, 6.2)</td>
<td>3.6 (3.1, 4.1)</td>
</tr>
<tr>
<td>Hazard ratio (95% CI)</td>
<td>0.69 (0.56, 0.85)</td>
<td></td>
</tr>
<tr>
<td>p-value(^c)</td>
<td></td>
<td>0.0006</td>
</tr>
<tr>
<td><strong>Progression-Free Survival</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of events, N (%)</td>
<td>287 (85)</td>
<td>156 (92)</td>
</tr>
<tr>
<td>Hazard ratio (95% CI)</td>
<td>0.56 (0.46, 0.68)</td>
<td></td>
</tr>
<tr>
<td>p-value(^c)</td>
<td></td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

\(^a\) Kaplan-Meier estimates
\(^b\) Methodology of Brookmeyer and Crowley
\(^c\) Stratified log-rank test (strata: ECOG PS, prior ramucirumab treatment, region), 2-sided

Figure 2  Kaplan-Meier Curves of Overall Survival in TAGS

15  REFERENCES

16 HOW SUPPLIED/STORAGE AND HANDLING

LONSURF 15 mg/6.14 mg tablets are supplied as white, biconvex, round, film-coated tablet, imprinted with ‘15’ on one side, and ‘102’ and ‘15 mg’ on the other side, in gray ink. The tablets are packaged in HDPE bottles with child resistant closures in the following presentations:

- 20 count: NDC 64842-1025-1
- 40 count: NDC 64842-1025-2
- 60 count: NDC 64842-1025-3

LONSURF 20 mg/8.19 mg tablets are supplied as pale red, biconvex, round, film-coated tablet, imprinted with ‘20’ on one side, and ‘102’ and ‘20 mg’ on the other side, in gray ink. The tablets are packaged in HDPE bottles with child resistant closures in the following presentations:

- 20 count: NDC 64842-1020-1
- 40 count: NDC 64842-1020-2
- 60 count: NDC 64842-1020-3

Store at 20°C to 25°C (68°F to 77°F); excursions are permitted from 15°C to 30°C (59°F to 86°F) [See USP Controlled Room Temperature].

LONSURF is a cytotoxic drug. Follow applicable special handling and disposal procedures.\(^1\)

If stored outside of original bottle, discard after 30 days.

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Severe Myelosuppression

Advise patients to immediately contact their healthcare provider if they experience signs or symptoms of infection and advise patients to keep all appointments for blood tests [see Warnings and Precautions (5.1)].

Gastrointestinal Toxicity

Advise patients to contact their healthcare provider for severe or persistent nausea, vomiting, diarrhea, or abdominal pain [see Adverse Reactions (6.1)].

Administration Instructions

Advise patients that LONSURF is available in two strengths and they may receive both strength tablets to provide the prescribed dosage.

Advise patients to take LONSURF with food [see Dosage and Administration (2.1)].

Advise patients that anyone else who handles their medication should wear gloves [see References (15)].
Embryo-Fetal Toxicity

Advise pregnant women and females of reproductive potential of the potential risk to the fetus. Advise females to inform their healthcare provider of a known or suspected pregnancy [see Warnings and Precautions (5.2), Use in Specific Populations (8.3)].

Advise female patients of reproductive potential to use effective contraception during treatment with LONSURF and for at least 6 months after the final dose [see Warnings and Precautions (5.2), Use in Specific Populations (8.3)].

Advise males with female partners of reproductive potential to use condoms during treatment with LONSURF and for at least 3 months after the final dose [see Use in Specific Populations (8.3), Nonclinical Toxicology (13.1)].

Lactation

Advise women not to breastfeed during treatment with LONSURF and for 1 day following the final dose [see Use in Specific Populations (8.2)].